Bray, F., Laversanne, M., Weiderpass, E. & Soerjomataram, I. The ever-increasing importance of cancer as a leading cause of premature death worldwide. Cancer 127, 3029–3030 (2021).
Google Scholar
Fares, J., Fares, M. Y., Khachfe, H. H., Salhab, H. A. & Fares, Y. Molecular principles of metastasis: a hallmark of cancer revisited. Signal Transduct. Target. Ther. 5, 28 (2020).
Google Scholar
Global Burden of Disease Cancer, C. et al. Cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life years for 29 cancer groups from 2010 to 2019: a systematic analysis for the Global Burden of Disease Study 2019. JAMA Oncol. 8, 420–444 (2022).
Google Scholar
Jin, L. et al. Breast cancer lung metastasis: molecular biology and therapeutic implications. Cancer Biol. Ther. 19, 858–868 (2018).
Google Scholar
Torti, D. & Trusolino, L. Oncogene addiction as a foundational rationale for targeted anti-cancer therapy: promises and perils. EMBO Mol. Med. 3, 623–636 (2011).
Google Scholar
Slamon, D. J. et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244, 707–712 (1989).
Google Scholar
Mishra, R., Hanker, A. B. & Garrett, J. T. Genomic alterations of ERBB receptors in cancer: clinical implications. Oncotarget 8, 114371–114392 (2017).
Google Scholar
Talia, K. L., Banet, N. & Buza, N. The role of HER2 as a therapeutic biomarker in gynaecological malignancy: potential for use beyond uterine serous carcinoma. Pathology 55, 8–18 (2023).
Google Scholar
O’Shaughnessy, J., Gradishar, W., O’Regan, R. & Gadi, V. Risk of recurrence in patients with HER2+ early-stage breast cancer: literature analysis of patient and disease characteristics. Clin Breast Cancer 23, 350–362 (2023).
Google Scholar
Cortés, J. et al. Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer: long-term survival analysis of the DESTINY-Breast03 trial. Nat. Med. 30, 2208–2215 (2024).
Google Scholar
Swain, S. M., Shastry, M. & Hamilton, E. Targeting HER2-positive breast cancer: advances and future directions. Nat. Rev. Drug. Discov. 22, 101–126 (2023).
Google Scholar
Scheck, M. K., Hofheinz, R. D. & Lorenzen, S. HER2-positive gastric cancer and antibody treatment: state of the art and future developments. Cancers 16, 1336 (2024).
Google Scholar
Meric-Bernstam, F. et al. Efficacy and safety of trastuzumab deruxtecan in patients with HER2-expressing solid tumors: primary results from the DESTINY-PanTumor02 Phase II Trial. J. Clin. Oncol. 42, 47–58 (2024).
Google Scholar
Guidi, L., Pellizzari, G., Tarantino, P., Valenza, C. & Curigliano, G. Resistance to antibody-drug conjugates targeting HER2 in breast cancer: molecular landscape and future challenges. Cancers 15, 1130 (2023).
Google Scholar
Doi, T. et al. Safety, pharmacokinetics, and antitumour activity of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody-drug conjugate, in patients with advanced breast and gastric or gastro-oesophageal tumours: a phase 1 dose-escalation study. Lancet Oncol. 18, 1512–1522 (2017).
Google Scholar
Shi, Y. et al. Efficacy, safety, and genetic analysis of furmonertinib (AST2818) in patients with EGFR T790M mutated non-small-cell lung cancer: a phase 2b, multicentre, single-arm, open-label study. Lancet Respir. Med. 9, 829–839 (2021).
Google Scholar
Wala, J. A. & Hanna, G. J. Chimeric antigen receptor T-cell therapy for solid tumors. Hematol. Oncol. Clin. North Am. 37, 1149–1168 (2023).
Google Scholar
Wen, M. et al. Combination of EGFR-TKIs with chemotherapy versus chemotherapy or EGFR-TKIs alone in advanced NSCLC patients with EGFR mutation. Biologics 12, 183–190 (2018).
Google Scholar
Schlam, I. & Swain, S. M. HER2-positive breast cancer and tyrosine kinase inhibitors: the time is now. npj Breast Cancer 7, 56 (2021).
Google Scholar
Skorda, A., Bay, M. L., Hautaniemi, S., Lahtinen, A. & Kallunki, T. Kinase inhibitors in the treatment of ovarian cancer: current state and future promises. Cancers 14, 6257 (2022).
Google Scholar
Malaguti, P., D’Aloia, M. M. & Alimandi, M. The ErbB2 receptor in gastric cancer. the quick-change artist. Transl. Gastrointest. Cancer 4, 282–293 (2015).
Google Scholar
Arienti, C., Pignatta, S. & Tesei, A. Epidermal growth factor receptor family and its role in gastric cancer. Front. Oncol. 9, 1308 (2019).
Google Scholar
Chung, H. K. et al. A compact synthetic pathway rewires cancer signaling to therapeutic effector release. Science 364, eaat6982 (2019).
Google Scholar
Waterman, H. & Yarden, Y. Molecular mechanisms underlying endocytosis and sorting of ErbB receptor tyrosine kinases. FEBS Lett. 490, 142–152 (2001).
Google Scholar
Titze, M. I. et al. A generic viral dynamic model to systematically characterize the interaction between oncolytic virus kinetics and tumor growth. Eur. J. Pharm. Sci. 97, 38–46 (2017).
Google Scholar
Garbutt, M. et al. Properties of replication-competent vesicular stomatitis virus vectors expressing glycoproteins of filoviruses and arenaviruses. J. Virol. 78, 5458–5465 (2004).
Google Scholar
Anderson, E. M. & Coller, B.-A. G. Translational success of fundamental virology: a VSV-vectored Ebola vaccine. J. Virol. 98, e0162723 (2024).
Google Scholar
Russell, S. J. & Peng, K. W. Measles virus for cancer therapy. Curr. Top. Microbiol. Immunol. 330, 213–241 (2009).
Google Scholar
Lovatt, C. & Parker, A. L. Oncolytic viruses and immune checkpoint inhibitors: the ‘hot’ new power couple. Cancers 15, 4178 (2023).
Google Scholar
Nemerow, G. & Flint, J. Lessons learned from adenovirus (1970-2019). FEBS Lett. 593, 3395–3418 (2019).
Google Scholar
Zheng, X. et al. Adenoviral E1a expression levels affect virus-selective replication in human cancer cells. Cancer Biol. Ther. 4, 1255–1262 (2005).
Google Scholar
Huang, H. et al. Oncolytic adenovirus programmed by synthetic gene circuit for cancer immunotherapy. Nat. Commun. 10, 4801 (2019).
Google Scholar
Zhang, R., Cui, Y., Guan, X. & Jiang, X. A recombinant human adenovirus type 5 (H101) combined with chemotherapy for advanced gastric carcinoma: a retrospective cohort study. Front. Oncol. 11, 752504 (2021).
Google Scholar
Bazan-Peregrino, M. et al. Comparison of molecular strategies for breast cancer virotherapy using oncolytic adenovirus. Hum. Gene Ther. 19, 873–886 (2008).
Google Scholar
Cheng, P. H., Wechman, S. L., McMasters, K. M. & Zhou, H. S. Oncolytic replication of E1b-deleted adenoviruses. Viruses 7, 5767–5779 (2015).
Google Scholar
Garber, K. China approves world’s first oncolytic virus therapy for cancer treatment. J. Natl Cancer Inst. 98, 298–300 (2006).
Google Scholar
Zhang, Y. et al. Intraperitoneal oncolytic virotherapy for patients with malignant ascites: Characterization of clinical efficacy and antitumor immune response. Mol. Ther. Oncolytics 25, 31–42 (2022).
Google Scholar
Fields, B. N., Knipe, D. M. & Howley, P. M. Fields Virology (Wolters Kluwer Health/Lippincott Williams & Wilkins, 2007).
Novella, I. S., Ball, L. A. & Wertz, G. W. Fitness analyses of vesicular stomatitis strains with rearranged genomes reveal replicative disadvantages. J. Virol. 78, 9837–9841 (2004).
Google Scholar
Gaddy, D. F. & Lyles, D. S. Vesicular stomatitis viruses expressing wild-type or mutant M proteins activate apoptosis through distinct pathways. J. Virol. 79, 4170–4179 (2005).
Google Scholar
Rogers, C. et al. Cleavage of DFNA5 by caspase-3 during apoptosis mediates progression to secondary necrotic/pyroptotic cell death. Nat. Commun. 8, 14128 (2017).
Google Scholar
Lundstrom, K. Self-replicating vehicles based on negative strand RNA viruses. Cancer Gene Ther. 30, 771–784 (2023).
Google Scholar
Cook, J. et al. Clinical activity of single-dose systemic oncolytic VSV virotherapy in patients with relapsed refractory T-cell lymphoma. Blood Adv. 6, 3268–3279 (2022).
Google Scholar
Finkelshtein, D., Werman, A., Novick, D., Barak, S. & Rubinstein, M. LDL receptor and its family members serve as the cellular receptors for vesicular stomatitis virus. Proc. Natl Acad. Sci. USA 110, 7306–7311 (2013).
Google Scholar
Das, S. C. & Pattnaik, A. K. Phosphorylation of vesicular stomatitis virus phosphoprotein P is indispensable for virus growth. J. Virol. 78, 6420–6430 (2004).
Google Scholar
Beier, K. T. et al. Anterograde or retrograde transsynaptic labeling of CNS neurons with vesicular stomatitis virus vectors. Proc. Natl Acad. Sci. USA 108, 15414–15419 (2011).
Google Scholar
Harrington, K., Freeman, D. J., Kelly, B., Harper, J. & Soria, J. C. Optimizing oncolytic virotherapy in cancer treatment. Nat. Rev. Drug Discov. 18, 689–706 (2019).
Google Scholar
Maliandi, M. V. et al. AduPARE1A and gemcitabine combined treatment trigger synergistic antitumor effects in pancreatic cancer through NF-kappaB mediated uPAR activation. Mol. Cancer 14, 146 (2015).
Google Scholar
Mei, S., Chen, X., Wang, K. & Chen, Y. Tumor microenvironment in ovarian cancer peritoneal metastasis. Cancer Cell Int. 23, 11 (2023).
Google Scholar
Safra, T. et al. Weekly carboplatin and paclitaxel: a retrospective comparison with the three-weekly schedule in first-line treatment of ovarian cancer. Oncologist 26, 30–39 (2021).
Google Scholar
Popa, A. et al. Genomic epidemiology of superspreading events in Austria reveals mutational dynamics and transmission properties of SARS-CoV-2. Sci. Transl. Med. 12, eabe2555 (2020).
Google Scholar
Zhang, Y. & Nagalo, B. M. Immunovirotherapy based on recombinant vesicular stomatitis virus: where are we?. Front. Immunol. 13, 898631 (2022).
Google Scholar
Su, Y. et al. Novel NanoLuc substrates enable bright two-population bioluminescence imaging in animals. Nat. Methods 17, 852–860 (2020).
Google Scholar
Bressy, C., Droby, G. N., Maldonado, B. D., Steuerwald, N. & Grdzelishvili, V. Z. Cell cycle arrest in G2/M phase enhances replication of interferon-sensitive cytoplasmic RNA viruses via inhibition of antiviral gene expression. J. Virol. 93, e01885–18 (2019).
Google Scholar
Bourgeois-Daigneault, M. C. et al. Combination of Paclitaxel and MG1 oncolytic virus as a successful strategy for breast cancer treatment. Breast Cancer Res. 18, 83 (2016).
Google Scholar
Bargmann, C. I., Hung, M. C. & Weinberg, R. A. Multiple independent activations of the neu oncogene by a point mutation altering the transmembrane domain of p185. Cell 45, 649–657 (1986).
Google Scholar
Lun, X. et al. Effects of intravenously administered recombinant vesicular stomatitis virus (VSV(deltaM51)) on multifocal and invasive gliomas. J. Natl Cancer Inst. 98, 1546–1557 (2006).
Google Scholar
Engel, E. R. & Walter, J. E. Rituximab and eculizumab when treating nonmalignant hematologic disorders: infection risk, immunization recommendations, and antimicrobial prophylaxis needs. Hematology Am. Soc. Hematol. Educ. Program 2020, 312–318 (2020).
Google Scholar
Manz, R. A., Thiel, A. & Radbruch, A. Lifetime of plasma cells in the bone marrow. Nature 388, 133–134 (1997).
Google Scholar
Alping, P. et al. Cancer risk for fingolimod, natalizumab, and rituximab in multiple sclerosis patients. Ann. Neurol. 87, 688–699 (2020).
Google Scholar
Damsky, W. et al. B cell depletion or absence does not impede anti-tumor activity of PD-1 inhibitors. J. Immunother. Cancer 7, 153 (2019).
Google Scholar
Sarvaria, A., Madrigal, J. A. & Saudemont, A. B cell regulation in cancer and anti-tumor immunity. Cell. Mol. Immunol. 14, 662–674 (2017).
Google Scholar
Murakami, Y. et al. Increased regulatory B cells are involved in immune evasion in patients with gastric cancer. Sci. Rep. 9, 13083 (2019).
Google Scholar
Hutzler, S. et al. Antigen-specific oncolytic MV-based tumor vaccines through presentation of selected tumor-associated antigens on infected cells or virus-like particles. Sci. Rep. 7, 16892 (2017).
Google Scholar
Anglesio, M. S. et al. Type-specific cell line models for type-specific ovarian cancer research. PLoS ONE 8, e72162 (2013).
Google Scholar
Hallas-Potts, A., Dawson, J. C. & Herrington, C. S. Ovarian cancer cell lines derived from non-serous carcinomas migrate and invade more aggressively than those derived from high-grade serous carcinomas. Sci. Rep. 9, 5515 (2019).
Google Scholar
Koopman, T. et al. HER2 immunohistochemistry in endometrial and ovarian clear cell carcinoma: discordance between antibodies and with in-situ hybridisation. Histopathology 73, 852–863 (2018).
Google Scholar
Yeo, M. K., Kim, S., Yoo, H. J., Suh, K. S. & Kim, K. H. HER2 expression in peritoneal dissemination of high-grade serous ovarian carcinoma: a comparative study of immunohistochemical reactivity using four HER2 antibodies. J. Clin. Med. 11, 6963 (2022).
Google Scholar
Guchelaar, N. A. D. et al. Intraperitoneal chemotherapy for unresectable peritoneal surface malignancies. Drugs 83, 159–180 (2023).
Google Scholar
Deshet-Unger, N. et al. Comparing intraperitoneal and intravenous personalized ErbB2CAR-T for the treatment of epithelial ovarian cancer. Biomedicines 10, 2216 (2022).
Google Scholar
van der Noll, R. et al. Phase I study of intermittent olaparib capsule or tablet dosing in combination with carboplatin and paclitaxel (part 2). Invest. New Drugs 38, 1096–1107 (2020).
Google Scholar
Tang, H. et al. Estrone-conjugated PEGylated liposome Co-loaded paclitaxel and carboplatin improve anti-tumor efficacy in ovarian cancer and reduce acute toxicity of chemo-drugs. Int. J. Nanomedicine 17, 3013–3041 (2022).
Google Scholar
West, H. et al. Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 20, 924–937 (2019).
Google Scholar
Tewari, K. S. et al. Final overall survival of a randomized trial of bevacizumab for primary treatment of ovarian cancer. J. Clin. Oncol. 37, 2317–2328 (2019).
Google Scholar
Ricciuti, B. et al. Association of high tumor mutation burden in non-small cell lung cancers with increased immune infiltration and improved clinical outcomes of PD-L1 blockade across PD-L1 expression levels. JAMA Oncol. 8, 1160–1168 (2022).
Google Scholar
Morand, S., Devanaboyina, M., Staats, H., Stanbery, L. & Nemunaitis, J. Ovarian cancer immunotherapy and personalized medicine. Int. J. Mol. Sci. 22, 6532 (2021).
Google Scholar
Sha, D. et al. Tumor mutational burden as a predictive biomarker in solid tumors. Cancer Discov. 10, 1808–1825 (2020).
Google Scholar
Kim, M. S. & Prasad, V. Pembrolizumab for all. J. Cancer Res. Clin. Oncol. 149, 1357–1360 (2023).
Google Scholar
Kottke, T. et al. Use of biological therapy to enhance both virotherapy and adoptive T-cell therapy for cancer. Mol. Ther. 16, 1910–1918 (2008).
Google Scholar
Qiao, J. et al. Cyclophosphamide facilitates antitumor efficacy against subcutaneous tumors following intravenous delivery of reovirus. Clin. Cancer Res. 14, 259–269 (2008).
Google Scholar
Robak, E. & Robak, T. Bruton’s kinase inhibitors for the treatment of immunological diseases: current status and perspectives. J. Clin. Med. 11, 2807 (2022).
Google Scholar
Rozkiewicz, D., Hermanowicz, J. M., Kwiatkowska, I., Krupa, A. & Pawlak, D. Bruton’s tyrosine kinase inhibitors (BTKIs): review of preclinical studies and evaluation of clinical trials. Molecules 28, 2400 (2023).
Google Scholar
Jenks, N. et al. Safety studies on intrahepatic or intratumoral injection of oncolytic vesicular stomatitis virus expressing interferon-beta in rodents and nonhuman primates. Hum. Gene Ther. 21, 451–462 (2010).
Google Scholar
Obuchi, M., Fernandez, M. & Barber, G. N. Development of recombinant vesicular stomatitis viruses that exploit defects in host defense to augment specific oncolytic activity. J. Virol. 77, 8843–8856 (2003).
Google Scholar
Marquis, K. A., Becker, R. L., Weiss, A. N., Morris, M. C. & Ferran, M. C. The VSV matrix protein inhibits NF-κB and the interferon response independently in mouse L929 cells. Virology 548, 117–123 (2020).
Google Scholar
Moerdyk-Schauwecker, M. et al. Resistance of pancreatic cancer cells to oncolytic vesicular stomatitis virus: role of type I interferon signaling. Virology 436, 221–234 (2013).
Google Scholar
Bayne, R. S. et al. MAP3K7 and CHD1 are novel mediators of resistance to oncolytic vesicular stomatitis virus in prostate cancer cells. Mol. Ther. Oncolytics 17, 496–507 (2020).
Google Scholar
Geoffroy, K., Mullins-Dansereau, V., Leclerc-Desaulniers, K., Viens, M. & Bourgeois-Daigneault, M.-C. Oncolytic vesicular stomatitis virus alone or in combination with JAK inhibitors is effective against ovarian cancer. Mol. Ther. Oncol. 32, 200826 (2024).
Google Scholar
Marrocco, I. & Yarden, Y. Resistance of lung cancer to EGFR-specific kinase inhibitors: activation of bypass pathways and endogenous mutators. Cancers 15, 5009 (2023).
Google Scholar
Reslan, L., Dalle, S. & Dumontet, C. Understanding and circumventing resistance to anticancer monoclonal antibodies. MAbs 1, 222–229 (2009).
Google Scholar
Lu, Y. & Zhao, F. Strategies to overcome tumour relapse caused by antigen escape after CAR T therapy. Mol. Cancer 24, 126 (2025).
Google Scholar
Petroni, G., Buque, A., Coussens, L. M. & Galluzzi, L. Targeting oncogene and non-oncogene addiction to inflame the tumour microenvironment. Nat. Rev. Drug Discov. 21, 440–462 (2022).
Google Scholar
Ayala Breton, C. et al. Oncolytic potency of HER-2 retargeted VSV-FH hybrid viruses: the role of receptor ligand affinity. Mol. Ther. Oncolytics 2, 15012 (2015).
Google Scholar
Gao, Y. & Bergman, I. Vesicular stomatitis virus (VSV) G glycoprotein can be modified to create a Her2/Neu-targeted VSV that eliminates large implanted mammary tumors. J. Virol. 97, e0037223 (2023).
Google Scholar
Yu, B. et al. Engineered cell entry links receptor biology with single-cell genomics. Cell 185, 4904–4920.e22 (2022).
Google Scholar
Fischer, S., Proschmann, U., Akgün, K. & Ziemssen, T. Lymphocyte counts and multiple sclerosis therapeutics: between mechanisms of action and treatment-limiting side effects. Cells 10, 3177 (2021).
Google Scholar
Costacurta, F., Rauch, S., von Laer, D. & Heilmann, E. Using vesicular stomatitis virus as a platform for directed protease evolution. Curr. Protoc. 4, e70074 (2024).
Google Scholar
Zou, X. & Lin, M. “Rewiring oncogenic signaling to precision ablation of metastatic cancer” cell and animal images. Zenodo https://doi.org/10.5281/zenodo.19296313 (2026).
